Privately-held German firm Immatics Biotechnologies has entered into a research collaboration and license… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Or, if you're only interested in reading the content about a specific topic (generics, biosimilars, coronavirus/COVID-19, digital pharma, Asia Pacific), then you can take our £10 per month channel subscription offer, which gives you access to all our news articles and in-depth content on this subject.
Germany 's Immatics Biotechnologies has signed a partnership agreement with Danish biotech firm catalyst . They 'll combine their technologies to develop several stem cell - specific bispecific immunotherapies against cancer . Under the financial terms of the deal , Immatics will get a $ 54 m initial investment , up to $ 550 m in " milestone " funding and tiered royalties on pharmaceutical sales . Genmab has the option to expand the partnership if it is economically viable .